Overview
Mirrors of Medicine offers interactive, case-based CME programmes focusing on oncology topics including bladder, breast, prostate cancer, and renal cell carcinoma. The programmes translate new data from key congresses and peer-reviewed papers into clinical practice through online, virtual, and in-person learning opportunities, including the PinPoint Case Platform and EACCME-accredited Global Forum.
In the news
- Is improving disease control enough when an overall survival advantage remains statistically unproven? The final LITESPARK-011 results raise important questions for the future treatment sequencing of advanced ccRCC. https://lnkd.in/eJVT3f6g Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti–PD-(L)1 therapy Final LITESPARK-011 results reinforce belzutifan 🧪 plus lenvatinib as a potential treatment option for advanced
- Our friend and Global Forum faculty member Dr. Petros Grivas is a candidate for the ASCO Nominating Committee 🌟 ➡️ Cast your vote by Wednesday, 2 December, 3 PM EST via this link: https://lnkd.in/g7ch7v9S
- Can we turn recurrence reduction into a long-term survival benefit in early breast cancer? The latest 6️⃣ year NATALEE results offer encouraging evidence that we may be moving closer. https://lnkd.in/ee-QeNPE Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2– early breast cancer: Six-year follow-up of the NATALEE trial The prespecified 6-year NATALEE analysis reinforces the long-term benefit of adding ribociclib to a nonsteroidal aromatase inhibitor 💊 (NSAI) in
- Could DASL-HiCaP influence how we manage non-metastatic prostate cancer with high-risk features? New data presented at ESMO 2026 provide an important opportunity to revisit treatment decisions in this setting. In this short video, a clinical case serves as the starting point to explore the DASL-HiCaP findings and consider their potential implications for clinical practice. 🎥 Watch the video for a concise overview of the data and reflections on how they may translate into everyday practice: https://lnkd.in/eBm3FGW5
- Fresh from ESMO 2026 🔬 Catch up on some of the latest results in oncology presented at the congress. Plus, Jeremy Blanc shares his expert perspective on the VOLGA trial, evaluating perioperative durvalumab + enfortumab vedotin, with or without tremelimumab, in muscle-invasive bladder cancer. 👉 Read the latest Mirrors of Medicine newsletter below.
- Fresh from ESMO 2026 🔬 Catch up on some of the latest results in oncology presented at the congress. Plus, Jeremy Blanc shares his expert perspective on the VOLGA trial, evaluating perioperative durvalumab + enfortumab vedotin, with or without tremelimumab, in muscle-invasive bladder cancer. 👉 Read the latest Mirrors of Medicine newsletter below.
- Great to see that the first regional APCCC satellite meeting for the HRBG region was a success, bringing together perspectives from Hungary, Bulgaria, Romania and Greece!
- Great to see that the first regional APCCC satellite meeting for the HRBG region was a success, bringing together perspectives from Hungary, Bulgaria, Romania and Greece!
Something wrong or missing? Send an update. Fixed within 24 hours.